BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

459 related articles for article (PubMed ID: 30229421)

  • 21. Retrospective validation of a new diagnostic criterion for hepatocellular carcinoma on gadoxetic acid-enhanced MRI: can hypointensity on the hepatobiliary phase be used as an alternative to washout with the aid of ancillary features?
    Joo I; Lee JM; Lee DH; Jeon JH; Han JK
    Eur Radiol; 2019 Apr; 29(4):1724-1732. PubMed ID: 30255250
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Imaging features of gadoxetic acid-enhanced MR imaging for evaluation of tumor-infiltrating CD8 cells and PD-L1 expression in hepatocellular carcinoma.
    Sun L; Mu L; Zhou J; Tang W; Zhang L; Xie S; Chen J; Wang J
    Cancer Immunol Immunother; 2022 Jan; 71(1):25-38. PubMed ID: 33993366
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Imaging features of subcentimeter hypointense nodules on gadoxetic acid-enhanced hepatobiliary phase MR imaging that progress to hypervascular hepatocellular carcinoma in patients with chronic liver disease.
    Jang KM; Kim SH; Kim YK; Choi D
    Acta Radiol; 2015 May; 56(5):526-35. PubMed ID: 24838304
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prediction of HCC microvascular invasion with gadobenate-enhanced MRI: correlation with pathology.
    Zhang L; Yu X; Wei W; Pan X; Lu L; Xia J; Zheng W; Jia N; Huo L
    Eur Radiol; 2020 Oct; 30(10):5327-5336. PubMed ID: 32367417
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prediction of microvascular invasion of hepatocellular carcinoma using gadoxetic acid-enhanced MR and (18)F-FDG PET/CT.
    Ahn SY; Lee JM; Joo I; Lee ES; Lee SJ; Cheon GJ; Han JK; Choi BI
    Abdom Imaging; 2015 Apr; 40(4):843-51. PubMed ID: 25253426
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Small (≤1-cm) hepatocellular carcinoma: diagnostic performance and imaging features at gadoxetic acid-enhanced MR imaging.
    Yu MH; Kim JH; Yoon JH; Kim HC; Chung JW; Han JK; Choi BI
    Radiology; 2014 Jun; 271(3):748-60. PubMed ID: 24588677
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Added value of hepatobiliary phase gadoxetic acid-enhanced MRI for diagnosing hepatocellular carcinoma in high-risk patients.
    Phongkitkarun S; Limsamutpetch K; Tannaphai P; Jatchavala J
    World J Gastroenterol; 2013 Dec; 19(45):8357-65. PubMed ID: 24363528
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nomogram for Predicting Microvascular Invasion in Hepatocellular Carcinoma Using Gadoxetic Acid-Enhanced MRI and Intravoxel Incoherent Motion Imaging.
    Zhou L; Qu Y; Quan G; Zuo H; Liu M
    Acad Radiol; 2024 Feb; 31(2):457-466. PubMed ID: 37491178
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Can LI-RADS imaging features at gadoxetic acid-enhanced MRI predict aggressive features on pathology of single hepatocellular carcinoma?
    Wei H; Jiang H; Liu X; Qin Y; Zheng T; Liu S; Zhang X; Song B
    Eur J Radiol; 2020 Nov; 132():109312. PubMed ID: 33022551
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Non-hypervascular hepatobiliary phase hypointense nodules on gadoxetic acid-enhanced MR can help determine the treatment method for HCC.
    Lee DH; Lee JM; Yu MH; Hur BY; Yi NJ; Lee KW; Suh KS; Yoon JH; Kim YJ; Lee JH; Yu SJ; Han JK
    Eur Radiol; 2019 Jun; 29(6):3122-3131. PubMed ID: 30643939
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Liver imaging reporting and data system (LI-RADS) v2018: comparison between computed tomography and gadoxetic acid-enhanced magnetic resonance imaging.
    Nakao S; Tanabe M; Okada M; Furukawa M; Iida E; Miyoshi K; Matsunaga N; Ito K
    Jpn J Radiol; 2019 Sep; 37(9):651-659. PubMed ID: 31321619
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Radiologic-Pathologic Correlation of Hepatobiliary Phase Hypointense Nodules without Arterial Phase Hyperenhancement at Gadoxetic Acid-enhanced MRI: A Multicenter Study.
    Joo I; Kim SY; Kang TW; Kim YK; Park BJ; Lee YJ; Choi JI; Lee CH; Park HS; Lee K; Kim H; Yu E; Kang HJ; Ha SY; Kim JY; Ahn S; Jung ES; Kim BH; Han HS; Lee JM
    Radiology; 2020 Aug; 296(2):335-345. PubMed ID: 32484414
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prediction of microvascular invasion of hepatocellular carcinoma: usefulness of peritumoral hypointensity seen on gadoxetate disodium-enhanced hepatobiliary phase images.
    Kim KA; Kim MJ; Jeon HM; Kim KS; Choi JS; Ahn SH; Cha SJ; Chung YE
    J Magn Reson Imaging; 2012 Mar; 35(3):629-34. PubMed ID: 22069244
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatobiliary MR contrast agent uptake as a predictive biomarker of aggressive features on pathology and reduced recurrence-free survival in resectable hepatocellular carcinoma: comparison with dual-tracer 18F-FDG and 18F-FCH PET/CT.
    Mulé S; Chalaye J; Legou F; Tenenhaus A; Calderaro J; Galletto Pregliasco A; Laurent A; Kharrat R; Amaddeo G; Regnault H; Tacher V; Kobeiter H; Itti E; Luciani A
    Eur Radiol; 2020 Oct; 30(10):5348-5357. PubMed ID: 32405753
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnostic performance of gadoxetic acid-enhanced liver MR imaging in the detection of HCCs and allocation of transplant recipients on the basis of the Milan criteria and UNOS guidelines: correlation with histopathologic findings.
    Lee DH; Lee JM; Baek JH; Shin CI; Han JK; Choi BI
    Radiology; 2015 Jan; 274(1):149-60. PubMed ID: 25203131
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Imaging Features of Gadoxetic Acid-enhanced and Diffusion-weighted MR Imaging for Identifying Cytokeratin 19-positive Hepatocellular Carcinoma: A Retrospective Observational Study.
    Choi SY; Kim SH; Park CK; Min JH; Lee JE; Choi YH; Lee BR
    Radiology; 2018 Mar; 286(3):897-908. PubMed ID: 29166246
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MR-imaging features of hepatocellular carcinoma capsule appearance in cirrhotic liver: comparison of gadoxetic acid and gadobenate dimeglumine.
    Dioguardi Burgio M; Picone D; Cabibbo G; Midiri M; Lagalla R; Brancatelli G
    Abdom Radiol (NY); 2016 Aug; 41(8):1546-54. PubMed ID: 27052455
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Peritumoral decreased uptake area of gadoxetic acid enhanced magnetic resonance imaging and tumor recurrence after surgical resection in hepatocellular carcinoma: A STROBE-compliant article.
    Shin SK; Kim YS; Shim YS; Choi SJ; Park SH; Jung DH; Kwon OS; Choi DJ; Kim JH
    Medicine (Baltimore); 2017 Aug; 96(33):e7761. PubMed ID: 28816953
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prediction of Microvascular Invasion in Hepatocellular Carcinoma: Preoperative Gd-EOB-DTPA-Dynamic Enhanced MRI and Histopathological Correlation.
    Huang M; Liao B; Xu P; Cai H; Huang K; Dong Z; Xu L; Peng Z; Luo Y; Zheng K; Peng B; Li ZP; Feng ST
    Contrast Media Mol Imaging; 2018; 2018():9674565. PubMed ID: 29606926
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of small (≤3 cm) hepatic lesions with atypical enhancement feature and hypointensity in hepatobiliary phase of gadoxetic acid-enhanced MRI in cirrhosis: A STARD-compliant article.
    Shin SK; Kim YS; Choi SJ; Shim YS; Jung DH; Kwon OS; Choi DJ; Kim JH
    Medicine (Baltimore); 2017 Jul; 96(29):e7278. PubMed ID: 28723741
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.